Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 196,794 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALL Clear all

Conditions: Sleep, Cardiovascular Risk Factor
Interventions: Regularized Sleep Schedule; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Maitland, Florida + 2 more

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Hepatitis C
Interventions: Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 35
States / cities: Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more

Conditions: Pneumonia
Interventions: chlorhexidine gluconate oral rinse (0.12%), placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Osteoarthritis
Interventions: Topical Tranexamic Acid, Intravenous Tranexamic Acid; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 100 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Spinal Cord Injuries (SCI)
Interventions: No Stimulation, Conventional tSCS, Spatiotemporal tSCS; Other · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 16 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B Cell Lymphoma, Lymphoma
Interventions: Ixazomib, Lenalidomide, Rituximab; Drug
Lead sponsor: Brian Hill; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Small-cell Lung Cancer, SCLC, Small Cell Lung Cancer Limited Stage
Interventions: Hippocampal-sparing Prophylactic Cranial Irradiation; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Charcot-Marie-Tooth Disease
Interventions: ACE-083, Placebo; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Orange, California • Aurora, Colorado • Gainesville, Florida + 13 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: Irinotecan, Bevacizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: New York, New York

Conditions: Healthy Women, Female Contraception
Interventions: levonorgestrel butanoate (LB) injection; Biological
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, celecoxib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY948862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 15,948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Eden Prairie, Minnesota

Conditions: Strabismus
Interventions: Not listed
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years to 88 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease
Interventions: Sulfur Hexafluoride, Ultrasound Elastography, Ultrasound Vascularity, Magnetic Resonance Enterography (MRE); Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pelvic Floor, Respiration
Interventions: Minimum expiration effort, Moderate expiration effort, Maximum expiration effort; Other
Lead sponsor: Kitani, Lenore, PT; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Liver Disease
Interventions: HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate), Hepatic Venous Pressure Gradient (HVPG); Drug · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Wounds
Interventions: no treatment; Other
Lead sponsor: Southwest Regional Wound Care Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Cancer Metastatic
Interventions: Nivolumab 480mg and surgical resection; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Nocturnal Hypoglycemia
Interventions: Dexcom G4 Platinum CGM, Activity monitor; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Year to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: 0 g pomace (control), 90 g pomace, 180 g pomace, Flavored water (control); Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 25
States / cities: Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 18 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Imeroprubart, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 33
States / cities: Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more

Search by objective public record fields.

Sleep Duration and Cardiovascular Health

A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical

Spatiotemporal tSCS in Spinal Cord Injury

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Mobile Medical Application for Cost-effective Strabismus Screening

Ultrasound Evaluation of Crohn's Disease

Pelvic Floor Activity and Breathing in Women

Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)

Collection of Samples for the Evaluation of Wound Biofilm in Acute and Chronic Wounds

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Adjusting Insulin Delivery to Activity

Citrus Beverages and Gastrointestinal Function

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)